LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

ABT

134.76

+1.17%↑

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

ABT

134.76

+1.17%↑

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

ABT

134.76

+1.17%↑

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

ABT

134.76

+1.17%↑

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

ABT

134.76

+1.17%↑

Search

Novo Nordisk A-S

Geschlossen

BrancheGesundheitswesen

64.34 -2.56

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

63.15

Max

66.07

Schlüsselkennzahlen

By Trading Economics

Einkommen

804M

29B

Verkäufe

-7.6B

78B

KGV

Branchendurchschnitt

19.19

56.602

EPS

6.53

Dividendenrendite

2.39

Gewinnspanne

37.182

Angestellte

76,302

EBITDA

5.9B

46B

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

+39.24% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

2.39%

2.45%

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

29B

295B

Vorheriger Eröffnungskurs

66.9

Vorheriger Schlusskurs

64.34

Nachrichtenstimmung

By Acuity

31%

69%

88 / 382 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bearish Evidence

Novo Nordisk A-S Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

12. Mai 2025, 09:36 UTC

Wichtige Markttreiber

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

7. Mai 2025, 11:29 UTC

Top News
Ergebnisse
Wichtige Markttreiber

Novo Nordisk Investors Breathe Sigh of Relief Despite Guidance Hit From Copycat Drugs -- 2nd Update

7. Mai 2025, 07:05 UTC

Ergebnisse

Novo Nordisk Cuts Guidance as Copycat Versions of Ozempic Hit Sales -- Update

7. Mai 2025, 06:19 UTC

Ergebnisse

Novo Nordisk Cuts Guidance as Copycat Versions of Ozempic Hit Sales

12. Mai 2025, 22:14 UTC

Top News

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12. Mai 2025, 18:45 UTC

Top News

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12. Mai 2025, 12:07 UTC

Market Talk

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

12. Mai 2025, 07:20 UTC

Market Talk

Pharma Shares Face Risks From Trump's Pricing Plans -- Market Talk

7. Mai 2025, 15:13 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Super Micro, AMD, Marvell, Disney, Uber, Arista, Sarepta, Charles River, and More -- Barrons.com

7. Mai 2025, 13:56 UTC

Ergebnisse

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

7. Mai 2025, 13:45 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Super Micro, AMD, Marvell, Disney, Uber, Nordisk, Sarepta, EA, Upstart, and More -- Barrons.com

7. Mai 2025, 11:25 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Super Micro, AMD, Disney, Uber, Novo Nordisk, Sarepta, EA, Tesla, and More -- Barrons.com

7. Mai 2025, 11:18 UTC

Ergebnisse

Novo Nordisk Stock Jumps After Earnings. It Cuts Guidance as Weight-Loss Drug Sales Slow. -- Barrons.com

7. Mai 2025, 09:55 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Super Micro, AMD, Novo Nordisk, Sarepta, EA, Rivian, Disney, and More -- Barrons.com

7. Mai 2025, 09:36 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Super Micro, AMD, Novo Nordisk, Sarepta, EA, Rivian, Tesla, and More -- Barrons.com

7. Mai 2025, 09:04 UTC

Ergebnisse
Heiße Aktien

Stocks to Watch Wednesday: Disney, Uber, Super Micro -- WSJ

7. Mai 2025, 08:10 UTC

Market Talk

Novo Nordisk Cuts Guidance Slightly More Than Expected -- Market Talk

7. Mai 2025, 08:08 UTC

Market Talk

Novo Nordisk's Downgraded Guidance Assumes Large Wegovy Uplift in 2H -- Market Talk

7. Mai 2025, 07:11 UTC

Market Talk
Ergebnisse

Novo Nordisk Shares Seen Under Pressure After Downgrade -- Market Talk

7. Mai 2025, 05:39 UTC

Ergebnisse

Novo Nordisk: Sales Outlook Assumes Reduction in Patients on Compounded GLP-1 Treatments During 2H25

7. Mai 2025, 05:38 UTC

Ergebnisse

Novo Nordisk 1Q Wegovy Drug Sales Rose 83% To DKK17.36B, Consensus Saw DKK18.5B

7. Mai 2025, 05:37 UTC

Ergebnisse

Novo Nordisk 1Q Ozempic Drug Sales Rose 15% To DKK32.72B, Consensus Saw DKK32.01B

7. Mai 2025, 05:36 UTC

Ergebnisse

Novo Nordisk 1Q Gross Margin 83.5% Vs 84.8%

7. Mai 2025, 05:35 UTC

Ergebnisse

Novo Nordisk: Focused on Preventing Unlawful Compounding and Further Expanding Access in US

7. Mai 2025, 05:34 UTC

Ergebnisse

Novo Nordisk: US Sales of Branded GLP-1 Treatments Impacted By Compounded Versions

7. Mai 2025, 05:34 UTC

Ergebnisse

Novo Nordisk: Sales Outlook Reflects Lower-Than-Planned Penetration of Branded GLP-1 Treatments in US

7. Mai 2025, 05:33 UTC

Ergebnisse

Novo Nordisk: Had Seen 2025 Op Profit Growth of 19%-27% in Constant Currency

7. Mai 2025, 05:33 UTC

Ergebnisse

Novo Nordisk: Had Seen 2025 Sales Growth of 16%-24% in Constant Currency

7. Mai 2025, 05:33 UTC

Ergebnisse

Novo Nordisk Now Sees 2025 Op Profit Growth of 16%-24% in Constant Currency

7. Mai 2025, 05:32 UTC

Ergebnisse

Novo Nordisk Now Sees 2025 Sales Growth of 13%-21% in Constant Currency

Peer-Vergleich

Kursveränderung

Novo Nordisk A-S Prognose

Kursziel

By TipRanks

39.24% Vorteil

12-Monats-Prognose

Durchschnitt 92.11 USD  39.24%

Hoch 136.647 USD

Tief 61 USD

Basierend auf 9 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Novo Nordisk A-S – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

9 ratings

3

Buy

5

Halten

1

Sell

Technischer Score

By Trading Central

62.63 / 69.23Unterstützung & Widerstand

Kurzfristig

Weak Bearish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

88 / 382 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Novo Nordisk A-S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.